KALAMAZOO, Michigan, USA, May 2, 2023 /PRNewswire/ -- Stryker (NYSE:SYK), one of the world's leading medical technology companies, announced today that it has completed the acquisition of Cerus Endovascular Ltd., a privately held commercial stage medical devices dedicated to the design and development of neurointerventional devices. for the treatment of intracranial aneurysms. Cerus Endovascular's CE marked products, the Contour Neurovascular System and the Neqstent coil-assisted flow diverter, will expand Stryker's current portfolio of aneurysm treatment solutions.
Technology for the endovascular treatment of aneurysms has been central to Stryker's Neurovascular division and the Cerus Endovascular portfolio will address the growing need for one-time intrasaccular aneurysm therapy.
"The acquisition of Cerus Endovascular greatly complements Stryker's neurovascular business and strengthens our hemorrhagic portfolio globally," said Jim Marucci, president of Stryker's Neurovascular division. "We look forward to working with the Cerus team to fulfill our mission of improving healthcare. Together, we will enable physicians to treat a broader range of aneurysms."
Stryker is one of the world's leading medical technology companies, working together with its customers to improve healthcare. The company offers innovative products and services in medicine and surgery, neurotechnology, orthopedics, and the spine that help improve patient outcomes and healthcare. Together with its clients around the world, Stryker affects more than 130 million patients a year. More information is available at www.stryker.com.
Media ContactLindsay HarrisGlobal Head of Digital, Marcom and Eventslindsay.email@example.com
Logo - https://mma.prnewswire.com/media/339565/...
View original content: https://www.prnewswire.com/news-releases/stryker-completa-la-adquisicion-de-cerus-endovascular-301812474.html